Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...910111213141516171819...3435»
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. (Pubmed Central) -  Sep 14, 2022   
    Immune checkpoint inhibitors, such as cemiplimab provide a globe-sparing option for the treatment of orbital squamous cell carcinoma. It is important to consider these agents especially when orbital exenteration is the alternative.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1 (Ballroom ABCD) -  Sep 14, 2022 - Abstract #IASLCNACLC2022IASLC_NACLC_39;    
    At 3 year follow-up, higher PD-L1 expression is still associated with improved outcomes for cemiplimab vs. chemotherapy as reflected by the main endpoints of ORR, PFS and OS, despite a high crossover rate. Continued cemiplimab with the addition of chemotherapy at the time of first progression provides a meaningful ORR and durable OS benefits.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh. (Pubmed Central) -  Sep 3, 2022   
    Biopsy confirmed chronic inflammation and fibrosis with no signs of malignancy. This unique case with dual primary cutaneous SCC provides support for cemiplimab in treating locally invasive periocular SCC, and potentially abrogating the need for highly morbid exenteration procedures to preserve binocular vision.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside. (Pubmed Central) -  Sep 3, 2022   
    Patients with TP53 mutations are more susceptible to develop cSCC, thus highlighting the importance of cell cycle regulation and also pointing towards the potential therapeutic targets within. This review illustrates the role of the programmed death receptor-1 (PD-1) inhibitor cemiplimab in treating advanced and metastatic cSCC not suitable to surgical excision and describes its development in the context of the translational research paradigm from preclinical studies to its licenced implementation in clinical care and beyond.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. (Pubmed Central) -  Sep 3, 2022   
    In the third case, cSCC presented itself as a large fungating mass that would have otherwise necessitated limb amputation and was successfully treated with 18 cycles of cemiplimab. This case highlights the dramatic response to cemiplimab obviating the need for surgical intervention and resulting in limb salvage.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Cost-Effectiveness Analysis of Cemiplimab for Patients with Advanced Non-Small Cell Lung Carcinoma in Spain (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1771;    
    Cemiplimab is anticipated to positively impact health outcomes in patients who would otherwise remain untreated, thus addressing significant unmet need in this population. Findings suggest that cemiplimab versus pembrolizumab is a cost-effective first-line treatment option for advanced NSCLC with PD-L1 expression ≥50% in Spain.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  R3767-ONC-1613: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers (clinicaltrials.gov) -  Aug 30, 2022   
    P1,  N=333, Active, not recruiting, 
    We report a case of an inoperable cSCC of the scalp extending into the sagittal sinus, now responding well to the monoclonal antibody Cemiplimab. Recruiting --> Active, not recruiting | N=669 --> 333 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
  • ||||||||||  PK/PD data, Review:  Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review. (Pubmed Central) -  Aug 28, 2022   
    Currently, there are fourteen analyses on PPK models of anti-PD-1 mAbs summarized in this review, including seven models that refer to nivolumab, four referring to pembrolizumab, one referring to cemiplimab, one referring to camrelizumab, and one referred to dostarlimab...Other less assessed significant covariates included lactate dehydrogenase (LDH), immunoglobulin G (IgG), ipilimumab coadministration (IPICO) on CL, and body mass index (BMI), malignant pleural mesothelioma (MESO) on V. This review provides detailed information about the characteristics of PPK models of anti-PD-1 mAbs, the effects of covariates on PK parameters, and the current status of the application of the models...Other potential covariates that were assessed less frequently but still have significance (e.g., LDH, IgG, and IPICO) should not be ignored. Thus, further research and thorough investigation are needed to assess new or potential covariates, which will pave the way for personalized anti-PD-1 mAbs therapy.
  • ||||||||||  Review, Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker:  Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. (Pubmed Central) -  Aug 27, 2022   
    In particular, phase three clinical trials, such as the IMpassion 130, the KEYNOTE-355 and the KEYNOTE-522 resulted in the approval of immunotherapeutic agents, such as atezolizumab and pembrolizumab by the US Food and Drug Administration in TNBC therapy. This review aims to present the huge potential of immunotherapy using monoclonal antibodies directed against immunosuppressive checkpoints-such as atezolizumab, avelumab, durvalumab, pembrolizumab, nivolumab, cemiplimab, tremelimumab, ipilimumab-in the fight against difficult to treat TNBCs as monotherapy as well as in more advanced combination strategies.
  • ||||||||||  pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
    Trial completion date, Trial primary completion date, Metastases:  A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) (clinicaltrials.gov) -  Aug 26, 2022   
    P1/2,  N=80, Recruiting, 
    This review aims to present the huge potential of immunotherapy using monoclonal antibodies directed against immunosuppressive checkpoints-such as atezolizumab, avelumab, durvalumab, pembrolizumab, nivolumab, cemiplimab, tremelimumab, ipilimumab-in the fight against difficult to treat TNBCs as monotherapy as well as in more advanced combination strategies. Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026